deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive... (respiratorydiseases. About deCODE ...)

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

Date:10/3/2008

respiratory diseases.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM) for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

About deCODE chemistry & biostructures

deCODE chemistry, Inc. & deCODE biostructures, Inc., are wholly-owned subsidiaries of deCODE genetics providing contract research services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. deCODE chemistry & biostructures takes a collaborative approach to pharmaceutical research services through a seamless integration of chemistry and biology c
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
3. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
4. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
5. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
6. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
7. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

Post Your Comments:

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive...(respiratorydiseases. About deCODE ...),Health